DEFB129 and neoplasm: Therapeutic vaccination of established highly aggressive and immunosuppressive ID8-Defβ29/Vegf-A (ID8DV) ovarian tumors [90,91] with the nonreplicating type I uracil auxotrophic vaccine strain CPS [5] was shown to preferentially target CD11c+ antigen presenting cells to reverse tumor associated immune suppression and promote tumor antigen specific CD8+ T cell dependent antitumor immunity [16–18].